Bone Marrow News and Research

RSS

Bone Marrow is the soft, sponge-like tissue in the center of most bones. It produces white blood cells, red blood cells, and platelets.

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

In a study that seems to pivot on a paradox, scientists at Dana-Farber Cancer Institute have used an immune system stimulant as an immune system suppressor to treat a common, often debilitating side effect of donor stem cell transplantation in cancer patients. The effect, in some cases, was profound.

1 Dec 2011

Cases of two AIDS patients renew hope of AIDS cure for many scientists, New York Times reports

The New York Times profiles two AIDS patients whose cases "suggest to many scientists that curing AIDS may be achievable," according to the newspaper. "One man, the so-called Berlin patient, apparently has cleared his HIV infection, albeit by arduous bone marrow transplants," and the other, "a 50-year-old man in Trenton, N.J., underwent a far less difficult gene therapy procedure. While he was not cured, his body was able to briefly control the virus after he stopped taking the usual antiviral drugs, something that is highly unusual," the newspaper writes.

29 Nov 2011

Growth hormone replacement increases bone formation in abdominally obese women

In a new study presented today at the annual meeting of the Radiological Society of North America (RSNA), growth hormone replacement for six months was found to increase bone formation in abdominally obese women.

29 Nov 2011

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Micromet, Inc. today announced that it has initiated a phase 2 trial of its lead product candidate blinatumomab (MT103) in adult patients with relapsed or refractory (r/r) B-precursor acute lymphoblastic leukemia (ALL). Blinatumomab is the first of a new class of agents called BiTE® antibodies, designed to harness the body's T cells to kill cancer cells.

28 Nov 2011

Transplantation of tissue-engineered windpipe can benefit patients with tracheal cancer

Tracheal tumors can be surgically removed, but most are too large for the surgery to be successful by the time they are discovered. Therefore, new therapeutic options are needed. Even in patients with operable tumors, the proportion of complete tumor resection is less than 60%. This outcome would be greatly improved if a trachea substitute with similar anatomical, physiological and biomechanical properties of the patient's original trachea were available.

24 Nov 2011

Physicians can do better if they learn from their failures

When seeking a physician, you should look for one with experience. Right? Maybe not. Research on physicians' decision-making processes has revealed that those who pay attention to failures as well as successes become more adept at selecting the correct treatment.

24 Nov 2011

Two-drug combination may alleviate radiation sickness in people

A combination of two drugs may alleviate radiation sickness in people who have been exposed to high levels of radiation, even when the therapy is given a day after the exposure occurred, according to a study led by scientists from Dana-Farber Cancer Institute and Children's Hospital Boston.

24 Nov 2011

GPS at WUSTL now offers new cancer genetic test

Physicians can now take advantage of a new genetics test -- one of the first of its kind to be offered in the United States -- that can help determine the best treatment for cancer patients.

23 Nov 2011

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

As the "recycling plant" of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes on its own waste. Cancer cells, in particular, are very sensitive because they need the proteasome for their uncontrolled growth. Biochemists at the Technische Universitaet Muenchen (TUM) have now identified the lead structure of a new class of drugs that attacks the proteasome in an unusual way. New medication could be developed on the basis of this previously unknown binding mechanism.

22 Nov 2011

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that REVLIMID (lenalidomide) has been granted approval by the Swiss agency for Therapeutic Products (Swissmedic) for use in patients with transfusion-dependent anemia due to low-or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality with or without additional cytogenic abnormalities.

21 Nov 2011

Study examines how mice with genetic bone defects respond to infusions of BMMSC

A new study in Nature Medicine describes how different types of immune system T-cells alternately discourage and encourage stem cells to regrow bone and tissue, bringing into sharp focus the importance of the transplant recipient's immune system in stem cell regeneration.

21 Nov 2011

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

The U.S. Food and Drug Administration today approved Erwinaze to treat patients with acute lymphoblastic leukemia (ALL), who have developed an allergy (hypersensitivity) to E. coli derived asparaginase and pegaspargase chemotherapy drugs used to treat ALL.

18 Nov 2011

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Factors such as low hemoglobin levels, increased systolic blood pressure, and male gender are linked to a higher risk of silent cerebral infarcts (SCIs), or silent strokes, in children with sickle cell anemia (SCA), according to results from a large, first-of-its-kind study published online today in Blood, the Journal of the American Society of Hematology (ASH).

17 Nov 2011

Researchers identify potential marker for leukemic relapse

The development of simple tests to predict a leukemic relapse in young patients is a step closer thanks to researchers from the Sainte-Justine University Hospital Research Center and the University of Montreal. Approximately 20 percent of young leukemia patients who are treated with stem cells derived from umbilical cord blood will experience leukemic relapse.

17 Nov 2011

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

Incyte Corporation today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for Jakafi (ruxolitinib) for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF.

17 Nov 2011

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

ZIOPHARM Oncology, Inc., a drug development company employing small molecule and synthetic biology approaches to cancer therapy, announced today new preclinical data from two separate studies of darinaparsin, a novel organic arsenic, in various solid tumor models at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 12-16 in San Francisco.

16 Nov 2011

Researchers to begin drug development projects for rare and neglected diseases

Researchers will begin drug development projects for rare and neglected diseases that include potential treatments for a musculoskeletal disorder, a cognitive dysfunction disorder, a virus that affects the central nervous system of newborns, a parasitic worm infection, a form of muscular dystrophy and a rare lung disease.

16 Nov 2011

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

A research network led by a Mayo Clinic physician found that stem cells obtained from bone marrow delivered two to three weeks after a person has a heart attack did not improve heart function.

15 Nov 2011

Stem cell injections within two weeks may not help in post heart attack recovery

University Hospitals Case Medical Center researchers could still be close to giving heart attack patients a second chance-just not as they originally thought.

15 Nov 2011

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

KAEL-GemVax, a leading oncology biopharmaceutical company, today announced that results from a Phase II trial (CTN-2006) in Stage III non-small cell lung cancer (NSCLC) patients vaccinated with the telomerase peptide GV1001 after chemoradiotherapy and an 8-year update from a phase I/II trial have been published in the November issue of Clinical Cancer, the journal of the American Association for Cancer Research.

15 Nov 2011

Bone Marrow News and Research

Further Reading

Immune system stimulant used as suppressor to treat chronic graft-versus-host disease

Cases of two AIDS patients renew hope of AIDS cure for many scientists, New York Times reports

Growth hormone replacement increases bone formation in abdominally obese women

Micromet commences blinatumomab phase 2 trial for r/r B-precursor acute lymphoblastic leukemia

Transplantation of tissue-engineered windpipe can benefit patients with tracheal cancer

Physicians can do better if they learn from their failures

Two-drug combination may alleviate radiation sickness in people

GPS at WUSTL now offers new cancer genetic test

Biochemists identify structure of hydroxyurea that specifically inhibits proteasome

Swissmedic approves REVLIMID for treatment of myelodysplastic syndromes

Study examines how mice with genetic bone defects respond to infusions of BMMSC

EUSA Pharma receives FDA approval for Erwinaze to treat ALL

Hemoglobin levels, blood pressure and male gender linked to higher risk of silent strokes in SCA children

Researchers identify potential marker for leukemic relapse

Incyte receives FDA approval for Jakafi to treat intermediate or high-risk MF

ZIOPHARM announces new preclinical data from two darinaparsin studies on solid tumors

Researchers to begin drug development projects for rare and neglected diseases

Stem cell therapy within 2 or 3 weeks does not improve heart function after attack

Stem cell injections within two weeks may not help in post heart attack recovery

Encouraging results from KAEL-GemVax GV1001 Phase II trial on NSCLC

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News